Linkage Disequilibrium between Polymorphisms of ABCB1 and ABCC2 to Predict the Treatment Outcome of Malaysians with Complex Partial Seizures on Treatment with Carbamazepine Mono-Therapy at the Kuala Lumpur Hospital
Purpose Carbamazepine (CBZ) is used as the first line of treatment of Complex Partial Seizures (CPS) in the Epilepsy Clinic, Neurology Department of Kuala Lumpur Hospital (KLH). More than 30% of the patients remain drug resistant to CBZ mono-therapy. CBZ is transported by the P-glycoprotein (P-gp). The P-gp encoded by the ABCB1 and ABCC2 genes are expressed in drug resistant patients with epilepsy. A few studies have shown significant association between CBZ resistant epilepsy and Linkage Disequilibrium (LD) with adjacent polymorphisms of these genes. Our study is aimed at determining the correlation between patients' response to CBZ mono-therapy to Single Nucleotide Polymorphisms G2677T and C3435T of the ABCB1 gene as well as G1249A and ？24C>T of the ABCC2 gene. Method 314 patients with CPS were recruited from the Neurology Department of the KLH based on stringent inclusion and exclusion criteria, of whom 152 were responders and the other 162 were non-responders. DNA was extracted from their blood samples and Taqman technology for allelic discrimination was performed. Results were described as genotype frequencies. The SHEsis analysis platform was used to calculate linkage disequilibrium index and infer haplotype frequencies. Haploview was used to do permutation test to obtain a corrected p-value. Results Resistance to treatment with CBZ mono-therapy was significantly associated with the 2677TT and the 3435TT genotypes while it was not significantly associated with the G1249A and ？24C>T polymorphisms. The GCGC haplotype combination of the 2677G>T, 3435C>T, 1249G>A and ？24C>T respectively was found to be extremely significant (p = 1.10e？20) with good drug response to CBZ mono-therapy. Conclusion Linkage disequilibrium between the 2677G>T, 3435C>T, 1249G>A and ？24C>T SNPs may be used as a reliable screening marker to determine the treatment outcome of CBZ mono-therapy with CPS irrespective of race or gender.
References
[1]
Engelborghs S, D′Hooge R, De Deyn PP (2000) Pathophysiology of epilepsy. Acta Neurol Belg 100: 201–213.
[2]
International League Alliance on Epilepsy (1981) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22: 489–501 doi:–10.1111/j.1528–1157.1981.tb06159.x.
[3]
Elizabeth C. (2011) Complex partial seizures. Available: http://emedicine.medscape.com/article/11？83962-overview. Accessed 10 August 2012.
[4]
Zakaria AK (1998) Principles of treatment of epilepsy. Mal J Med Scien 5: 11–17.
[5]
Pratap RC, Gururaj AK (1989) Clinical and electroencephalographic features of complex partial seizures in infants. Acta Neurol Scand 79: 123–127.
Miller JW (2007) Epilepsy surgery in the frontal lobe: terra incognita or new frontier? Epilepsy Curr 7: 98–99 doi: 10.1111/j.1535-7511.2007.00186.x.
[8]
Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, et al. (2006) ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7: 551–561 doi: 10.2217/14622416.7.4.551.
[9]
Haerian BS, Lim KS, Mohamed EH, Tan HJ, Tan CT, et al. (2011) Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure 20: 387–394 doi: 10.1016/j.seizure.2011.01.008.
[10]
Ozgon GO, Bebek N, Gul G, Cine N (2008) Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur Neurol 59: 67–70 doi: 10.1159/000109264.
[11]
Mosyagin I, Runge U, Schroeder HW, Dazert E, Vogelgesang S, et al. (2008) Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 49: 1555–1561 doi: –10.1111/j.1528–1167.2008.01661.x.
[12]
Grover S, Bala K, Sharma S, Gourie-Devi M, Baghel R, et al. (2010) Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie 92: 1207–1212 doi: 10.1016/j.biochi.2010.04.008.
[13]
Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, et al. (2009) Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab Pharmacokinet 24: 255–260 doi: 10.2133/dmpk.24.255.
[14]
Kim WJ, Lee JH, Yi J, Cho YJ, Heo K, et al. (2010) A nonsynonymous variation on MRP2/ABCC2 is associated with neurological adverse drug reactions of Carbamazapine in patients with epilepsy. Pharmacogenet Genomics 20: 249–256.
[15]
Yin Z, Su M, Li X, Li M, Ma R, et al. (2009) ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and adenocarcinoma risk in Chinese non-smoking females. J Exp Clin Cancer Res 28: 153 doi: 10.1186/1756-9966-28-153.
[16]
Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15: 97–98 doi: 10.1038/sj.cr.7290272.
[17]
Li Z, Zhang Z, He Z, Tang W, Li T, et al.. (2009) A partition-ligation-combination-subdivisi？onEM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res 19: : 519–523. doi: 10.1038/cr.2009.33.
[18]
Chaudhary PM, Mechetner EB, Roninson IB (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80: 2735–2739.
[19]
Eichelbaum M, Fromm MF, Schwab M (2004) Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26: 180–185.
[20]
Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423–429 doi: 10.1016/j.tips.2004.06.002.
[21]
Meissner K, Jedlitschky G, Meyer zu Schwabedissen H, Dazert P, Eckel L, et al. (2004) Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14: 381–385.
[22]
Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, et al. (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96: 3900–3905.
[23]
Saito T, Zhang ZJ, Ohtsubo T, Noda I, Shibamori Y, et al. (2001) Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol 121: 735–742.
[24]
Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1: 27–42.
[25]
Nakano T, Sekine S, Ito K, Horie T (2009) Correlation between apical localization of Abcc2/Mrp2 and phosphorylation status of ezrin in rat intestine. Drug Metab Dispos 37: 1521–1527 doi: 10.1124/dmd.108.024836.
[26]
Qiang L, Liwen W, Liri J, Qi X, Yan S (2007) Association analysis of a polymorphism of MDR1 gene and refractory temporal lobe epilepsy in a Chinese population. Neurol Asia 12: 94–95.
[27]
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm？ller J, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473–3478.
[28]
Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, et al. (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71: 297–303 doi: 10.1067/mcp.2002.122055.
[29]
Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, et al. (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18: 1400–1404.
[30]
Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, et al. (2009) Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 ？24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 19: 353–362.
[31]
Qu J, Zhou BT, Yin JY, Xu XJ, Zhao YC, et al. (2012) ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci Ther 18: 647–651 doi: –10.1111/j.1755–5949.2012.00336.x.
[32]
Kim DW, Lee SK, Chu K, Jang IJ, Yu KS, et al. (2009) Lack of association between ABCB1, ABCG2 and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res 84: 86–90.
